{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T15:58:55Z","timestamp":1765382335483,"version":"3.37.3"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T00:00:00Z","timestamp":1632700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T00:00:00Z","timestamp":1632700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Genesis Oncology Trust, New Zealand","award":["GOT 14S1-RPG"],"award-info":[{"award-number":["GOT 14S1-RPG"]}]},{"DOI":"10.13039\/501100001559","name":"Breast Cancer Foundation New Zealand","doi-asserted-by":"publisher","award":["F1603"],"award-info":[{"award-number":["F1603"]}],"id":[{"id":"10.13039\/501100001559","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The School of Medicine Foundation, University of Auckland, New Zealand"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s13318-021-00721-0","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T04:03:00Z","timestamp":1632715380000},"page":"817-820","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Severe 5-Fluorouracil-Associated Gastrointestinal Toxicity Unexplained by Dihydropyrimidine Dehydrogenase Deficiency and Renal Impairment: Should We Be Investigating Other Elimination Pathways to Assess the Risk of 5-Fluorouracil Toxicity?"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5984-1280","authenticated-orcid":false,"given":"Soo Hee","family":"Jeong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5843-3517","authenticated-orcid":false,"given":"Ottiniel","family":"Chavani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4951-3539","authenticated-orcid":false,"given":"Kathryn","family":"Burns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3115-8244","authenticated-orcid":false,"given":"David","family":"Porter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3305-9768","authenticated-orcid":false,"given":"Michael","family":"Findlay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6570-5368","authenticated-orcid":false,"given":"Nuala","family":"Helsby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,27]]},"reference":[{"issue":"1","key":"721_CR1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1200\/JCO.1994.12.1.14","volume":"12","author":"TR Buroker","year":"1994","unstructured":"Buroker TR, O\u2019Connell MJ, Wieand HS, Krook JE, Gerstner JB, Mailliard JA, Schaefer PL, Levitt R, Kardinal CG, Gesme DH Jr. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol. 1994;12(1):14\u201320.","journal-title":"J Clin Oncol"},{"issue":"4","key":"721_CR2","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3816\/CCC.2006.n.046","volume":"6","author":"CJ Twelves","year":"2006","unstructured":"Twelves CJ. Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: overview of efficacy, safety, and cost-effectiveness. Clin Colorectal Cancer. 2006;6(4):278\u201387.","journal-title":"Clin Colorectal Cancer"},{"issue":"11","key":"721_CR3","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1093\/annonc\/mdl284","volume":"17","author":"M Gusella","year":"2006","unstructured":"Gusella M, Crepaldi G, Barile C, Bononi A, Menon D, Toso S, Scapoli D, Stievano L, Ferrazzi E, Grigoletto F, Ferrari M, Padrini R. Pharmacokinetic and demographic markers of 5-fluorouracil toxicity in 181 patients on adjuvant therapy for colorectal cancer. Ann Oncol. 2006;17(11):1656\u201360.","journal-title":"Ann Oncol"},{"issue":"8","key":"721_CR4","first-page":"2203","volume":"47","author":"GD Heggie","year":"1987","unstructured":"Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res. 1987;47(8):2203\u20136.","journal-title":"Cancer Res"},{"issue":"4","key":"721_CR5","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3816\/CCC.2010.n.033","volume":"9","author":"J Ciccolini","year":"2010","unstructured":"Ciccolini J, Gross E, Dahan L, Lacarelle B, Mercier C. Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope? Clin Colorectal Cancer. 2010;9(4):224\u20138.","journal-title":"Clin Colorectal Cancer"},{"issue":"11","key":"721_CR6","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/bjc.2017.94","volume":"116","author":"D Meulendijks","year":"2017","unstructured":"Meulendijks D, Henricks LM, Jacobs BAW, Aliev A, Deenen MJ, de Vries N, Rosing H, van Werkhoven E, de Boer A, Beijnen JH, Mandigers C, Soesan M, Cats A, Schellens JHM. Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity. Br J Cancer. 2017;116(11):1415\u201324.","journal-title":"Br J Cancer"},{"key":"721_CR7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ejps.2015.10.001","volume":"81","author":"JA Duley","year":"2016","unstructured":"Duley JA, Ni M, Shannon C, Norris RL, Sheffield L, Harris M, van Kuilenburg AB, Mead S, Cameron A, Helsby N, George R, Charles BG. Towards a test to predict 5-fluorouracil toxicity: pharmacokinetic data for thymine and two sequential metabolites following oral thymine administration to healthy adult males. Eur J Pharm Sci. 2016;81:36\u201341.","journal-title":"Eur J Pharm Sci"},{"key":"721_CR8","first-page":"155","volume":"86","author":"N Helsby","year":"2019","unstructured":"Helsby N, Duley JA, Burns K, Bonnet C, Jeong SH, Brenman E, Barlow P, Sharples K, Porter D, Findlay M. An observational case-control study to assess the ability of the thymine challenge test to predict patients with severe to life threatening fluoropyrimidine-induced gastrointestinal toxicity. BJCP. 2019;86:155\u201364.","journal-title":"BJCP."},{"key":"721_CR9","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s00280-021-04240-2","volume":"87","author":"KE Burns","year":"2021","unstructured":"Burns KE, Chavani O, Jeong SH, Duley JA, Porter D, Findlay M, Strother RM, Helsby NA. Comparison of a thymine challenge test and endogenous uracil-dihydrouracil levels for assessment of fluoropyrimidine toxicity risk. Cancer Chemother Pharmacol. 2021;87:711\u20136.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"721_CR10","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2165\/00003088-198916040-00002","volume":"16","author":"RB Diasio","year":"1989","unstructured":"Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet. 1989;16(4):215\u201337.","journal-title":"Clin Pharmacokinet"},{"key":"721_CR11","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jpba.2017.04.055","volume":"142","author":"O Chavani","year":"2017","unstructured":"Chavani O, Jensen BP, Strother RM, Florkowski CM, George PM. Development, validation and application of a novel liquid chromatography tandem mass spectrometry assay measuring uracil, 5,6-dihydrouracil, 5-fluorouracil, 5,6-dihydro-5-fluorouracil, alpha-fluoro-beta-ureidopropionic acid and alpha-fluoro-beta-alanine in human plasma. J Pharm Biomed Anal. 2017;142:125\u201335.","journal-title":"J Pharm Biomed Anal"},{"issue":"4","key":"721_CR12","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1097\/FTD.0000000000000532","volume":"40","author":"JA Duley","year":"2018","unstructured":"Duley JA, Ni M, Shannon C, Norris RL, Sheffield L, Cowley D, Harris M, van Kuilenburg ABP, Helsby N, George R, Charles BG. Preliminary evidence for enhanced thymine absorption: a putative new phenotype associated with fluoropyrimidine toxicity in cancer patients. Ther Drug Monit. 2018;40(4):495\u2013502.","journal-title":"Ther Drug Monit"},{"issue":"9","key":"721_CR13","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00228-002-0534-6","volume":"58","author":"G Bocci","year":"2002","unstructured":"Bocci G, Danesi R, Allegrini G, Innocenti F, Di Paolo A, Falcone A, Conte PF, Del Tacca M. Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: a case report. Eur J Clin Pharmacol. 2002;58(9):593\u20135.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"721_CR14","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/j.1365-2125.1981.tb01304.x","volume":"12","author":"GT Tucker","year":"1981","unstructured":"Tucker GT. Measurement of the renal clearance of drugs. Br J Clin Pharmacol. 1981;12(6):761\u201370.","journal-title":"Br J Clin Pharmacol"},{"key":"721_CR15","doi-asserted-by":"crossref","unstructured":"Douglass HO Jr, Mittelman A. Metabolic studies of 5-fluorouracil. II. Influence of the route of administration on the dynamics of distribution in man. Cancer. 1974;34(6):1878\u201381.","DOI":"10.1002\/1097-0142(197412)34:6<1878::AID-CNCR2820340604>3.0.CO;2-C"},{"issue":"7","key":"721_CR16","first-page":"1357","volume":"17","author":"Y Suda","year":"1990","unstructured":"Suda Y, Akazawa S. Biliary and pancreatic excretion of methotrexate (MTX) and 5-FU on the MTX\/5-FU sequential therapy. Gan To Kagaku Ryoho. 1990;17(7):1357\u201363.","journal-title":"Gan To Kagaku Ryoho"},{"issue":"1","key":"721_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1055\/s-0037-1620542","volume":"21","author":"D Young","year":"1982","unstructured":"Young D, Vine E, Ghanbarpour A, Shani J, Siemsen JK, Wolf W. Metabolic and distribution studies with radiolabeled 5-fluorouracil. Nuklearmedizin. 1982;21(1):1\u20137.","journal-title":"Nuklearmedizin"},{"issue":"15","key":"721_CR18","doi-asserted-by":"publisher","first-page":"5439","DOI":"10.1073\/pnas.84.15.5439","volume":"84","author":"DJ Sweeny","year":"1987","unstructured":"Sweeny DJ, Barnes S, Heggie GD, Diasio RB. Metabolism of 5-fluorouracil to an N-cholyl-2-fluoro-beta-alanine conjugate: previously unrecognized role for bile acids in drug conjugation. Proc Natl Acad Sci USA. 1987;84(15):5439\u201343.","journal-title":"Proc Natl Acad Sci USA"},{"key":"721_CR19","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/bs.acr.2014.10.007","volume":"125","author":"AT Nies","year":"2015","unstructured":"Nies AT, Magdy T, Schwab M, Zanger UM. Role of ABC transporters in fluoropyrimidine-based chemotherapy response. Adv Cancer Res. 2015;125:217\u201343.","journal-title":"Adv Cancer Res"},{"issue":"6","key":"721_CR20","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1200\/JCO.2002.20.6.1491","volume":"20","author":"JA Sloan","year":"2002","unstructured":"Sloan JA, Goldberg RM, Sargent DJ, Vargas-Chanes D, Nair S, Cha SS, Novotny PJ, Poon MA, O\u2019Connell MJ, Loprinzi CL. Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol. 2002;20(6):1491\u20138.","journal-title":"J Clin Oncol"},{"issue":"6","key":"721_CR21","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1002\/cncr.20878","volume":"103","author":"K Chansky","year":"2005","unstructured":"Chansky K, Benedetti J, Macdonald JS. Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma. Cancer. 2005;103(6):1165\u201371.","journal-title":"Cancer"},{"issue":"2","key":"721_CR22","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s00280-012-2018-4","volume":"71","author":"F Mueller","year":"2013","unstructured":"Mueller F, B\u00fcchel B, K\u00f6berle D, Sch\u00fcrch S, Pfister B, Kr\u00e4henb\u00fchl S, Froehlich TK, Largiader CR, Joerger M. Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study. Cancer Chemother Pharmacol. 2013;71(2):361\u201370.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"721_CR23","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1200\/JCO.1992.10.7.1171","volume":"10","author":"G Milano","year":"1992","unstructured":"Milano G, Etienne MC, Cassuto-Viguier E, Thyss A, Santini J, Frenay M, Renee N, Schneider M, Demard F. Influence of sex and age on fluorouracil clearance. J Clin Oncol. 1992;10(7):1171\u20135.","journal-title":"J Clin Oncol"},{"issue":"2","key":"721_CR24","first-page":"1011","volume":"275","author":"EG Schuetz","year":"1995","unstructured":"Schuetz EG, Furuya KN, Schuetz JD. Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J Pharmacol Exp Ther. 1995;275(2):1011\u20138.","journal-title":"J Pharmacol Exp Ther"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-021-00721-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-021-00721-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-021-00721-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T09:35:38Z","timestamp":1637141738000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-021-00721-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,27]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["721"],"URL":"https:\/\/doi.org\/10.1007\/s13318-021-00721-0","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"type":"print","value":"0378-7966"},{"type":"electronic","value":"2107-0180"}],"subject":[],"published":{"date-parts":[[2021,9,27]]},"assertion":[{"value":"9 September 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by Genesis Oncology Trust, New Zealand (grant number GOT 14SI-RPG), Breast Cancer Foundation New Zealand (grant number F1603), and The School of Medicine Foundation, University of Auckland, New Zealand. The funding sources had no involvement in the study design, the collection, analysis, and interpretation of data, the writing of the report, or the decision to submit the article for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no conflicts of interest to declare that are relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The datasets generated during and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee (Northern A Health and Disability Ethics Committee of NZ ref 14\/NTA\/186) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Patients signed informed consent regarding publishing their data.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SHJ: investigation, formal analysis, writing\u2014original draft, writing\u2014review and editing. OC: investigation. KB: investigation. DP: conceptualization, funding acquisition. MF: conceptualization, funding acquisition. NH: conceptualization, funding acquisition, formal analysis, writing\u2014original draft, writing\u2014review and editing.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}